The biosimilar developer, backed by Eli Lilly, Daaichi Sankyo and Medpace, will use the proceeds from its initial public offering to advance three of its product candidates.
Coherus BioSciences, a US-based developer of pharmaceutical biosimilars that is backed by pharmaceutical firm Eli Lilly, raised $85m when it went public on Nasdaq on Thursday.
Coherus issued almost 6.3 million shares priced at $13.50. Joint book-running managers J.P. Morgan Securities and Credit Suisse Securities and lead manager Cowen and Company have a 30-day option to acquire another 944,000 shares, which would boost the size of the offering to almost $97.8m.
Founded in 2010, Coherus is developing biosimilar versions of…
